4568N Stock Chart & Stats
$281.00
$0.00(0.00%)
At close: 4:00 PM EDT
$281.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$281.00 - $429.00
Previous CloseN/A
Volume0.00
Average Volume (3M)20.00
Market Cap
$547.84B
Enterprise Value$4.61M
Total Cash (Recent Filing)$637.85B
Total Debt (Recent Filing)$500.48B
Price to Earnings (P/E)20.8
Beta-0.17
Next Earnings
Oct 30, 2026EPS Estimate
4.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)132.10
Shares Outstanding1,862,893,300
10 Day Avg. Volume0
30 Day Avg. Volume20
Financial Highlights & Ratios
PEG Ratio-1.98
Price to Book (P/B)3.08
Price to Sales (P/S)2.41
P/FCF Ratio-100.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$439.77Price Target Upside56.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)16.47
Revenue Forecast (FY)$260.95B
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSustained revenue expansion indicates continued demand for Daiichi Sankyo’s prescription portfolio. Growth across oncology and other therapeutic areas can support scale, fund research, and strengthen the company’s global commercial position over the next several quarters.
Solid ProfitabilityA high gross margin and positive net margin demonstrate the economic strength of the pharmaceutical model and its specialty portfolio. These margins provide resources for ongoing R&D and commercialization, although maintaining them will depend on product mix and development spending.
Healthy Balance SheetLow-to-moderate leverage and respectable returns on equity provide financial flexibility for R&D, licensing, and market expansion. The sizeable equity base also offers resilience against earnings volatility and supports continued investment in long-cycle pharmaceutical programs.
Bears Say
Weak Cash ConversionNegative free cash flow despite reported profitability weakens internal funding capacity and may reflect working-capital swings or elevated investment. If sustained, poor cash conversion could constrain R&D, shareholder returns, and strategic flexibility despite the healthy balance sheet.
Margin CompressionThe decline in net margin shows that earnings quality has weakened from the prior year, even as revenue continues to grow. Persistent compression could reduce the benefits of scale and limit reinvestment capacity if product mix, pricing, or costs remain unfavorable.
Declining Earnings MomentumNegative EPS growth indicates that profit generation is currently lagging the company’s broader revenue expansion. This may signal pressure from costs, product mix, or investment intensity; continued divergence between sales and earnings would weaken operating leverage over the medium term.
Daiichi Sankyo Company News
4568N FAQ
What was Daiichi Sankyo Company Limited’s price range in the past 12 months?
Daiichi Sankyo Company Limited lowest stock price was $281.00 and its highest was $429.00 in the past 12 months.
What is Daiichi Sankyo Company Limited’s market cap?
Daiichi Sankyo Company Limited’s market cap is $547.84B.
When is Daiichi Sankyo Company Limited’s upcoming earnings report date?
Daiichi Sankyo Company Limited’s upcoming earnings report date is Oct 30, 2026 which is in 50 days.
How were Daiichi Sankyo Company Limited’s earnings last quarter?
Daiichi Sankyo Company Limited released its earnings results on Jul 31, 2026. The company reported $4.051 earnings per share for the quarter, missing the consensus estimate of $4.403 by -$0.353.
Is Daiichi Sankyo Company Limited overvalued?
According to Wall Street analysts Daiichi Sankyo Company Limited’s price is currently Undervalued.
Does Daiichi Sankyo Company Limited pay dividends?
Daiichi Sankyo Company Limited does not currently pay dividends.
What is Daiichi Sankyo Company Limited’s EPS estimate?
Daiichi Sankyo Company Limited’s EPS estimate is 4.25.
How many shares outstanding does Daiichi Sankyo Company Limited have?
Daiichi Sankyo Company Limited has 1,862,893,300 shares outstanding.
What happened to Daiichi Sankyo Company Limited’s price movement after its last earnings report?
Daiichi Sankyo Company Limited reported an EPS of $4.051 in its last earnings report, missing expectations of $4.403. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Daiichi Sankyo Company Limited?
Currently, no hedge funds are holding shares in MX:4568N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Daiichi Sankyo Company Limited
Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise actively involved in the research, development, manufacturing, importation, marketing, and distribution of a diverse array of medicinal products worldwide. Its extensive product lineup addresses numerous therapeutic areas. In oncology, key offerings include trastuzumab deruxtecan, an anti-HER2 antibody drug conjugate, alongside treatments like Gefitinib for malignant tumors, Bicalutamide for prostate cancer, and Tamoxifen, an anti-breast cancer agent. For pain management, the company provides mirogabalin and loxoprofen (an anti-inflammatory analgesic). Diabetes treatments feature teneligliptin/canagliflozin and teneligliptin, with colesevelam serving dual purposes for hypercholesterolemia and type 2 diabetes. Other notable prescription drugs include lacosamide (an anti-epileptic), prasugrel (an antiplatelet), denosumab (for osteoporosis and bone disorders), edoxaban (an anticoagulant), esomeprazole (for ulcer treatment), memantine (for Alzheimer's disease), and laninamivir (for influenza). The company also supplies olmesartan (an antihypertensive), levofloxacin (an antibacterial), pravastatin (for hypercholesterolemia), Silodosin (for dysuria), and ferric carboxymaltose/iron sucrose injections for anemia. Beyond prescription medications, Daiichi Sankyo markets popular consumer health brands such as Lulu (a combination cold remedy), Loxonin S (an antipyretic/anti-inflammatory painkiller), Transino (for melasma and skin improvement), Minon (skincare), and the oral care lines Breath Labo and Clean Dental. The company further contributes to public health with various vaccines, including adsorbed cell culture-derived influenza, influenza HA, measles-rubella combined, and mumps vaccines. Its operations also extend beyond human pharmaceuticals to include veterinary drugs, cosmetics, medical equipment, food products, drinking water, and the production of active pharmaceutical ingredients (APIs) and intermediates. Daiichi Sankyo is collaborating with Guardant Health on the development of Guardant360 CDx, a companion diagnostic for Enhertu, specifically for advanced metastatic non-small cell lung cancer. Founded in 1899, the company is headquartered in Tokyo, Japan.
4568N Company Deck
4568N Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a mixture of clear commercial and clinical momentum—notably strong ENHERTU and accelerating DATROWAY sales, major guideline and regulatory wins, significant milestone income, and favorable legal outcomes—counterbalanced by meaningful expense increases (SG&A and R&D), inventory-related charges and one‑off negative items that pressured reported operating profit. Pipeline execution remains active with several upcoming readouts and continued partnership activity, but there are near‑term cost and timing uncertainties (CMO negotiations, trial adjustments, regional generic pressure). Overall, the positives (robust top‑line growth, flagship product expansion, regulatory and legal wins, and upgraded DATROWAY guidance) outweigh the negatives, while management signals a cautious near‑term margin outlook to be addressed in the forthcoming five‑year plan.View all MX:4568N earnings summaries4568N Stock 12 Month Forecast
Average Price Target
$439.77
▲(56.50% Upside)